Nuritas’ Post

Manuka Honey for Dry Eye? -- Is manuka honey helpful for dry eyes when applied in an eye drop? Find out what research has shown in our article. Also, find out if mixing manuka honey into hot beverages deactivates its key compounds. https://bit.ly/47dHMkV

At Bacthera, quality is at the core of LBP manufacturing. 🔬   In the exploration of LBP manufacturing, as detailed by our CQO, Lorenz Rindisbacher, quality assurance emerges not merely as a benchmark but as a foundational pillar critical to the development of LBPs. The inherent complexity of live organisms demands a meticulous approach to ensure safety and efficacy.    Delve into the article (written in collaboration with our CTO, Tue Hodal) to reveal how this emphasis on quality shapes the future of microbiome therapies. 👉 https://lnkd.in/eirJgVfi

Read our latest newsletter "Secrets of Secretion - efficient protein production | 15+ years VALIDOGEN"

We are delighted to share today's The Wall Street Journal article featuring Fractyl Health, Inc. (Nasdaq: GUTS). Dr. Harith Rajagopalan, Fractyl Health's CEO, is quoted throughout Betsy McKay's article "The Quest for Treatments to Keep Weight Off After Ozempic." In it, he says, "The unmet need has shifted from how do you lose weight to how do you keep it off." Uniquely positioned in the market, Fractyl Health is working on two therapies, Revita® and Rejuva®, to help people keep the weight off. https://lnkd.in/g8QrnVDc   #BioTech #Innovation #Obesity #Type2Diabetes     *In the United States, Revita is for investigational use only under US law.   **The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. 

Leveraging 6 decades of microbiology knowledge to impact human health and safety in pharmaceuticals, nutraceuticals, food, and cannabis to further amplify the support and impact to the cannabis industry:  https://lnkd.in/gCHYBvzJ #cannabisindustry #cannabismicrobiology #humanhealth #consumersafety #productsafety #cannabisscience

Sanofi might not be done with the 'weight loss space' after all. That unsurprising observation -- a $100 billion drug market produces its own gravitational field, exerting power over a massive body of economic systems that sit next to it -- comes from Endpoints News in its coverage of Sanofi's presentation at #JPM24. "After its own GLP-1 drug failed a mid-stage trial almost half a decade ago, the French drugmaker missed out on what has become the biggest new drug category of the decade. On Wednesday at the JP Morgan Healthcare Conference, top executives at the company said they could look at potential next-generation products in the years to come that could be more targeted or have better side effects. “There are genetic signals on where to dig for obesity drugs 2.0,” Sanofi’s head of R&D Houman Ashrafian said. That could include better identifying patients who will respond to more targeted drugs, work to improve the treatments’ side effects, or exploring drugs that could help underweight or frail patients. That would fit with a broader trend by other pharma companies that haven’t yet cracked into the blockbuster market now dominated by Novo Nordisk and Eli Lilly and Company. Almost all see the demand for weight loss product to continue to grow, with plenty of room for more players and new, more advanced treatments." It's not just "demand", it's hyper-demand. And it presents PhRMA with a unique opportunity to invent leverage around the "value" of GLP-1s, to power earnings not just from a 'drug market' alone, but the wealth of an entire nation. Just ask Nestlé / Nestlé Health Science, which said it was working on 'companion products' to accompany drugs like Ozempic, Wegovy and Mounjaro. Where the rest of the food market is struggling is navigating the 'transition space' to new era, in #positioning strategy for the world of GLP-1s. Because it's hard re-engineering a plane into a helicopter while in flight. So the default is to rally around the past and defend the economic system (and career path) that has made you successful so far. In the case of the food industry, it's a commercial model worth around $2 trillion in annual revenue in the United States alone. How long that model lasts is another question. Greater attention to processing marks a major new challenge for food makers, writes Jesse Newman here. "Makers of goods from ice cream to pasta sauce are stepping up lobbying, pushing back as the U.S. government probes the health effects of heavily processed food. It is a new front in a struggle that could reshape America’s approach to nutrition and threaten profits for companies behind foods throughout much of the supermarket." Perhaps next year at J.P. Morgan, we'll see a presentation with the food market interoperating with the drug market as a single economic system on the real "weight loss space". #ThinkEcosystems

There's only a couple more hours to visit bioMérieux Booth 208 at IAFP. ⏳ Here are 3 things you don't want to miss out on: 1️⃣ Seeing our instruments in-person, including our new, sleek VIDAS® KUBE™ 2️⃣ Hearing first-hand from our experts how Change Is Possible in your organization 3️⃣ Learning about our xPRO™ Program innovations, including GENE-UP® Pathogenic E.coli (PEC), which dramatically reduces false positive rates, and GENE-UP® PRO BEVERAGE which detects spoilage in high-acid beverages (plus many more!) #IAFP2023 #FoodSafety

How did C15:0, the newest essential #fattyacid come to market? We embraced the #science, the skeptics, and above all, our determination to make a positive change in the world. Read more in our Q&A with NutraIngredients, out today!